Počet záznamov: 1
zidovudín
SYS d015215 LBL 00000cz--a2200000o--4500 005 20250606214010.8 008 920509|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 065 $a D03.383.742.680.705.950 065 $a D13.570.230.500.950 065 $a D13.570.230.855.950 065 $a D13.570.685.705.950 066 $a 01 $c 03 150 $a zidovudín $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Azidothymidine $2 eng 450 $w v $a AZT (Antiviral) $2 eng 450 $w v $a azidotymidín $2 slo 450 $w v $a AZT (antivírusový) $2 slo 550 $7 sllk_us_auth*d000963 $Y Antimetabolites $w P $a antimetabolity 550 $7 sllk_us_auth*d018894 $Y Reverse Transcriptase Inhibitors $w P $a inhibítory reverznej transkriptázy 550 $7 sllk_us_auth*d019380 $Y Anti-HIV Agents $w P $a látky proti HIV 665 $a 89 $2 eng 665 $a Thymidine/analogs & derivatives (1975-1988) $2 eng 680 9-
$i A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. $2 eng 750 -2
$a Zidovudine $2 eng 980 $x M
Počet záznamov: 1